Baker Brothers portfolio, Q1 2025
Baker Bros. Advisors · 13F for the quarter ending Mar 31, 2025
For Q1 2025, Baker Bros. Advisors reported $9B across 89 US-listed positions, led by ONC (26.5%), INCY (20.6%) and ACAD (7.9%). Compared with its filing for Q4 2024, Baker Brothers opened 4 new positions, added to 11, reduced 16 and sold out of 10; 58 positions did not change.
The largest purchase was an addition to IMVT ($64.1M); the largest sale, a reduction of ONC ($199.5M).
Key facts
- 13F portfolio value
- $9BQ1 2025
- Positions
- 89
- Largest holding
- ONC 26.5%
- New positions
- 4
- Sold out
- 10
- Filed
- May 15, 2025
Holdings as of (Q1 2025), filed with the SEC on . Changes are measured against the filing for Dec 31, 2024. Every tracked investor's Q1 2025 13F.
Bought and sold in Q1 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Beone Medicines LtdONC | ▼ Reduced 7.7% | −732.83K | $199.5M | 2.21% |
| Immunovant IncIMVT | ▲ Added 220% | +3.75M | $64.1M | 0.71% |
Ionis Pharmaceuticals Incno ticker on file | ▼ Sold out | — | $29.5M | 0.33% |
| Insmed IncINSM | ▲ Added 7.5% | +373.76K | $28.5M | 0.32% |
| Krystal Biotech IncKRYS | ▼ Sold out | −169.93K | $26.6M | 0.29% |
| Rhythm Pharmaceuticals IncRYTM | ▼ Reduced 7.9% | −479.77K | $25.4M | 0.28% |
| Immunocore Holdings plcIMCR | ▲ Added 53% | +807.34K | $24M | 0.27% |
| Vaxcyte IncPCVX | ▲ Added more than 10× | +592K | $22.4M | 0.25% |
| CRISPR Therapeutics AGCRSP | ▼ Reduced 50% | −653.91K | $22.3M | 0.25% |
Akero Therapeutics Incno ticker on file | ▼ Reduced 50% | −548.37K | $22.2M | 0.25% |
| Xenon Pharmaceuticals IncXENE | ▼ Reduced 65% | −646.27K | $21.7M | 0.24% |
| argenx SEARGX | ▼ Reduced 31% | −34.14K | $20.2M | 0.22% |
| Celcuity IncCELC | ▲ Added 59% | +1.58M | $16M | 0.18% |
Verona Pharma Plcno ticker on file | ▲ New | +223.84K | $14.2M | 0.16% |
| Alkermes PLCALKS | ▲ Added 7.2% | +301.53K | $10M | 0.11% |
Merus N Vno ticker on file | ▼ Reduced 50% | −226.5K | $9.5M | 0.11% |
| Neurogene IncNGNE | ▲ Added 120% | +811.75K | $9.5M | 0.11% |
| Mirum Pharmaceuticals IncMIRM | ▼ Sold out | −190.48K | $7.9M | 0.09% |
| Arvinas IncARVN | ▼ Sold out | −405.58K | $7.8M | 0.09% |
| Rocket Pharmaceuticals IncRCKT | ▲ Added more than 10× | +1M | $6.7M | 0.07% |
| Biomea Fusion IncBMEA | ▼ Sold out | −1.45M | $5.6M | 0.06% |
Regulus Therapeutics Incno ticker on file | ▲ New | +2.69M | $4.7M | 0.05% |
| Sionna Therapeutics IncSION | ▲ New | +400K | $4.2M | 0.05% |
| Vir Biotechnology IncVIR | ▼ Reduced 50% | −542K | $3.5M | 0.04% |
| Candel Therapeutics IncCADL | ▼ Reduced 18% | −544.79K | $3.1M | 0.03% |
| Arcturus Therapeutics HoldingsARCT | ▼ Sold out | −151.33K | $2.6M | 0.03% |
| Compass Therapeutics IncCMPX | ▼ Reduced 65% | −1.01M | $1.9M | 0.02% |
| Tectonic Therapeutic IncTECX | ▲ New | +100K | $1.8M | 0.02% |
Mersana Therapeutics Incno ticker on file | ▼ Sold out | −1.09M | $1.6M | 0.02% |
| PTC Therapeutics IncPTCT | ▼ Sold out | −20.4K | $920.9K | 0.01% |
| Sana Biotechnology IncSANA | ▼ Reduced 15% | −350K | $588K | 0.01% |
| PMV Pharmaceuticals IncPMVP | ▼ Sold out | −322.02K | $486.3K | 0.01% |
| Century Therapeutics IncIPSC | ▼ Reduced 70% | −555.78K | $264.6K | 0.00% |
| Sera Prognostics IncSERA | ▲ Added 1.2% | +63.77K | $234.7K | 0.00% |
Leap Therapeutics Incno ticker on file | ▼ Reduced 65% | −767.43K | $234.1K | 0.00% |
| Foghorn Therapeutics IncFHTX | ▼ Sold out | −45.03K | $212.5K | 0.00% |
| Cerus CorpCERS | ▼ Reduced 0.7% | −126.25K | $175.5K | 0.00% |
| Acrivon Therapeutics IncACRV | ▼ Reduced 57% | −30.08K | $61.1K | 0.00% |
| Incyte CorpINCY | ▲ Added 0.00% | +487 | $29.5K | 0.00% |
IGM Biosciences Incno ticker on file | ▲ Added 0.02% | +953 | $1.1K | 0.00% |
Opthea Limitedno ticker on file | ▼ Reduced 4.0% | −86.3K | $0 | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| 1 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 26.5% | $2.4B | 8.8M | $272.17 | 4+ qtrs | ▼ Reduced 7.7% |
| 2 | Incyte CorpINCY | Health Care | 20.6% | $1.9B | 30.74M | $60.55 | 4+ qtrs | ▲ Added 0.00% |
| 3 | Acadia Pharmaceuticals IncACAD | — | 7.88% | $712.2M | 42.88M | $16.61 | 4+ qtrs | No change |
| 4 | Madrigal Pharmaceuticals IncMDGL | Health Care | 7.24% | $654M | 1.97M | $331.23 | 4+ qtrs | No change |
| 5 | Summit Therapeutics IncSMMT | Health Care | 5.21% | $471.2M | 24.42M | $19.29 | 4+ qtrs | No change |
| 6 | Insmed IncINSM | Health Care | 4.54% | $410.5M | 5.38M | $76.29 | 4+ qtrs | ▲ Added 7.5% |
| 7 | Rhythm Pharmaceuticals IncRYTM | Health Care | 3.29% | $296.9M | 5.6M | $52.97 | 4+ qtrs | ▼ Reduced 7.9% |
| 8 | Revolution Medicines IncRVMD | Health Care | 3.11% | $280.7M | 7.94M | $35.36 | 4+ qtrs | No change |
| 9 | Kymera Therapeutics IncKYMR | Health Care | 1.82% | $164.1M | 6M | $27.37 | 4+ qtrs | No change |
| 10 | Alkermes PLCALKS · SHS | Health Care | 1.64% | $148M | 4.48M | $33.02 | 4+ qtrs | ▲ Added 7.2% |
| 11 | Edgewise Therapeutics IncEWTX | Health Care | 1.50% | $135.4M | 6.16M | $22.00 | 4+ qtrs | No change |
| 12 | Replimune Group IncREPL | — | 1.19% | $107.7M | 11.05M | $9.75 | 4+ qtrs | No change |
| 13 | Insmed Incno ticker on file · NOTE 0.75% 6/1/2028 | — | 1.12% | $101.6M | — | — | 4+ qtrs | No change |
| 14 | Immunovant IncIMVT | Health Care | 1.03% | $93.3M | 5.46M | $17.09 | 4+ qtrs | ▲ Added 220% |
| 15 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 1.02% | $92.4M | 10.89M | $8.49 | 4+ qtrs | No change |
| 16 | Immunocore Holdings plcIMCR · ADS | — | 0.76% | $68.9M | 2.32M | $29.67 | 4+ qtrs | ▲ Added 53% |
| 17 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.69% | $62.6M | 2.82M | $22.21 | 4+ qtrs | No change |
| 18 | Abcellera Biologics IncABCL | — | 0.68% | $61.4M | 27.53M | $2.23 | 4+ qtrs | No change |
| 19 | Ultragenyx PharmaceuticalRARE | — | 0.63% | $57.1M | 1.58M | $36.21 | 4+ qtrs | No change |
| 20 | Denali Therapeutics IncDNLI | — | 0.56% | $50.7M | 3.73M | $13.60 | 4+ qtrs | No change |
| 21 | Kodiak Sciences IncKOD | Health Care | 0.54% | $48.6M | 17.31M | $2.80 | 4+ qtrs | No change |
| 22 | Nurix Therapeutics IncNRIX | — | 0.51% | $46.1M | 3.88M | $11.88 | 4+ qtrs | No change |
| 23 | argenx SEARGX · SPONSORED ADR | Health Care | 0.51% | $46M | 77.76K | $591.86 | 4+ qtrs | ▼ Reduced 31% |
| 24 | Entrada Therapeutics IncTRDA | — | 0.49% | $44M | 4.87M | $9.04 | 4+ qtrs | No change |
| 25 | Celcuity IncCELC | — | 0.48% | $43M | 4.26M | $10.11 | 4+ qtrs | ▲ Added 59% |
| 26 | Grail IncGRAL | Health Care | 0.46% | $41.6M | 1.63M | $25.54 | 2 qtrs | No change |
| 27 | Roivant Sciences LtdROIV · SHS | Health Care | 0.42% | $38M | 3.77M | $10.09 | 4+ qtrs | No change |
| 28 | Immatics N.V.IMTX · SHS | — | 0.36% | $32.8M | 7.28M | $4.51 | 4+ qtrs | No change |
| 29 | Stoke Therapeutics IncSTOK | — | 0.34% | $30.8M | 4.63M | $6.65 | 4+ qtrs | No change |
| 30 | Cerus CorpCERS | — | 0.30% | $26.9M | 19.35M | $1.39 | 4+ qtrs | ▼ Reduced 0.7% |
| 31 | Vaxcyte IncPCVX | Health Care | 0.27% | $24.2M | 640.89K | $37.76 | 4+ qtrs | ▲ Added more than 10× |
| 32 | Monte Rosa Therapeutics IncGLUE | — | 0.25% | $22.8M | 4.92M | $4.64 | 4+ qtrs | No change |
| 33 | CRISPR Therapeutics AGCRSP · NAMEN AKT | Health Care | 0.25% | $22.3M | 654.1K | $34.03 | 4+ qtrs | ▼ Reduced 50% |
| 34 | Akero Therapeutics Incno ticker on file | — | 0.25% | $22.2M | 548.71K | $40.48 | 4+ qtrs | ▼ Reduced 50% |
| 35 | Sera Prognostics IncSERA · CLASS A COM | — | 0.22% | $20.2M | 5.5M | $3.68 | 4+ qtrs | ▲ Added 1.2% |
| 36 | Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS | — | 0.20% | $17.6M | 1.23M | $14.38 | 4+ qtrs | No change |
| 37 | Neurogene IncNGNE | — | 0.19% | $17.4M | 1.49M | $11.71 | 4+ qtrs | ▲ Added 120% |
| 38 | IDEAYA Biosciences IncIDYA | — | 0.19% | $17.4M | 1.06M | $16.38 | 4+ qtrs | No change |
| 39 | Verona Pharma Plcno ticker on file · SPONSORED ADS | — | 0.16% | $14.2M | 223.84K | $63.49 | 1 qtr | New |
| 40 | Candel Therapeutics IncCADL | — | 0.15% | $13.8M | 2.44M | $5.65 | 2 qtrs | ▼ Reduced 18% |
| 41 | Praxis Precision MedicinesPRAX | Health Care | 0.14% | $12.6M | 331.53K | $37.87 | 4+ qtrs | No change |
| 42 | 2seventy bio Incno ticker on file | — | 0.14% | $12.3M | 2.5M | $4.94 | 4+ qtrs | No change |
| 43 | Xenon Pharmaceuticals IncXENE | — | 0.13% | $11.7M | 347.41K | $33.55 | 4+ qtrs | ▼ Reduced 65% |
| 44 | Bicara Therapeutics IncBCAX | — | 0.12% | $10.9M | 833.33K | $13.03 | 3 qtrs | No change |
| 45 | Ionis Pharmaceuticals IncIONS | Health Care | 0.12% | $10.8M | 357.92K | $30.17 | 3 qtrs | No change |
| 46 | Dbv Technologies S A SponsoredDBVT · SPONSORED ADS | — | 0.11% | $10M | 1.46M | $6.82 | 4+ qtrs | No change |
| 47 | Alumis IncALMS | — | 0.11% | $9.6M | 1.56M | $6.14 | 4+ qtrs | No change |
| 48 | Merus N Vno ticker on file | — | 0.10% | $9.4M | 223.5K | $42.09 | 4+ qtrs | ▼ Reduced 50% |
| 49 | Prelude Therapeutics IncPRLD | — | 0.09% | $7.8M | 10.12M | $0.7680 | 4+ qtrs | No change |
| 50 | Verve Therapeutics Incno ticker on file | — | 0.09% | $7.7M | 1.69M | $4.57 | 4+ qtrs | No change |
| 51 | Rocket Pharmaceuticals IncRCKT | — | 0.08% | $7.3M | 1.1M | $6.67 | 2 qtrs | ▲ Added more than 10× |
| 52 | Xencor IncXNCR | — | 0.08% | $7.1M | 670.43K | $10.64 | 4+ qtrs | No change |
| 53 | Dyne Therapeutics IncDYN | — | 0.08% | $7M | 672.1K | $10.46 | 4+ qtrs | No change |
| 54 | KALA BIO IncKALA | — | 0.08% | $6.9M | 1.2M | $5.73 | 4+ qtrs | No change |
| 55 | Design Therapeutics IncDSGN | — | 0.07% | $6.7M | 1.74M | $3.86 | 4+ qtrs | No change |
| 56 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.07% | $6.3M | 361.57K | $17.31 | 3 qtrs | No change |
| 57 | Taysha Gene Therapies IncTSHA | — | 0.06% | $5.6M | 4M | $1.39 | 4+ qtrs | No change |
| 58 | Regulus Therapeutics Incno ticker on file | — | 0.05% | $4.7M | 2.69M | $1.75 | 1 qtr | New |
| 59 | IGM Biosciences Incno ticker on file | — | 0.05% | $4.7M | 4.1M | $1.15 | 4+ qtrs | ▲ Added 0.02% |
| 60 | Intellia Therapeutics IncNTLA | — | 0.05% | $4.6M | 644.12K | $7.11 | 2 qtrs | No change |
| 61 | Celldex Therapeutics IncCLDX | — | 0.05% | $4.5M | 247.64K | $18.15 | 4+ qtrs | No change |
| 62 | Sionna Therapeutics IncSION | — | 0.05% | $4.2M | 400K | $10.46 | 1 qtr | New |
| 63 | BioNTech SEBNTX · SPONSORED ADS | Health Care | 0.05% | $4.1M | 45.03K | $91.06 | 2 qtrs | No change |
| 64 | TScan Therapeutics IncTCRX | — | 0.04% | $3.8M | 2.78M | $1.38 | 4+ qtrs | No change |
| 65 | Disc Medicine IncIRON | — | 0.04% | $3.8M | 77.05K | $49.64 | 2 qtrs | No change |
| 66 | Vir Biotechnology IncVIR | — | 0.04% | $3.5M | 542.54K | $6.48 | 2 qtrs | ▼ Reduced 50% |
| 67 | Sana Biotechnology IncSANA | — | 0.04% | $3.4M | 2.03M | $1.68 | 4+ qtrs | ▼ Reduced 15% |
| 68 | Sagimet Biosciences IncSGMT | — | 0.03% | $3.1M | 953K | $3.26 | 4+ qtrs | No change |
| 69 | Relay Therapeutics IncRLAY | — | 0.03% | $3M | 1.16M | $2.62 | 4+ qtrs | No change |
| 70 | Wave Life Sciences LtdWVE · SHS | — | 0.03% | $2.8M | 344.06K | $8.08 | 3 qtrs | No change |
| 71 | Fate Therapeutics IncFATE | — | 0.03% | $2.6M | 3.26M | $0.7901 | 4+ qtrs | No change |
| 72 | Skye Bioscience IncSKYE | — | 0.03% | $2.3M | 1.45M | $1.59 | 4+ qtrs | No change |
| 73 | Protara Therapeutics IncTARA | — | 0.03% | $2.3M | 536.83K | $4.26 | 4+ qtrs | No change |
| 74 | Enliven Therapeutics IncELVN | — | 0.03% | $2.3M | 114.83K | $19.68 | 4+ qtrs | No change |
| 75 | Contineum Therapeutics IncCTNM · CL A | — | 0.02% | $2.2M | 312.5K | $6.98 | 4+ qtrs | No change |
| 76 | Prime Medicine IncPRME | — | 0.02% | $2M | 1.03M | $1.99 | 4+ qtrs | No change |
| 77 | Tectonic Therapeutic IncTECX | — | 0.02% | $1.8M | 100K | $17.71 | 1 qtr | New |
| 78 | vTv Therapeutics IncVTVT · CL A | — | 0.02% | $1.7M | 97.31K | $17.32 | 4+ qtrs | No change |
| 79 | Compass Therapeutics IncCMPX | — | 0.01% | $1M | 547.5K | $1.90 | 4+ qtrs | ▼ Reduced 65% |
| 80 | Neumora Therapeutics IncNMRA | — | 0.01% | $1M | 1.03M | $1.00 | 4+ qtrs | No change |
| 81 | HOOKIPA Pharma Incno ticker on file | — | 0.01% | $877.8K | 812.81K | $1.08 | 4+ qtrs | No change |
| 82 | Generation Bio Cono ticker on file | — | 0.01% | $787.7K | 1.94M | $0.4050 | 4+ qtrs | No change |
| 83 | Aligos Therapeutics IncALGS | — | 0.01% | $685.2K | 83.06K | $8.25 | 4+ qtrs | No change |
| 84 | Leap Therapeutics Incno ticker on file | — | 0.00% | $123.5K | 404.74K | $0.3051 | 4+ qtrs | ▼ Reduced 65% |
| 85 | Century Therapeutics IncIPSC | — | 0.00% | $115K | 241.68K | $0.4760 | 4+ qtrs | ▼ Reduced 70% |
| 86 | Tyra Biosciences IncTYRA | — | 0.00% | $98.6K | 10.61K | $9.30 | 4+ qtrs | No change |
| 87 | Acrivon Therapeutics IncACRV | — | 0.00% | $46.3K | 22.81K | $2.03 | 4+ qtrs | ▼ Reduced 57% |
| 88 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $25K | 833.33K | $0.0300 | 4+ qtrs | No change |
| 89 | Opthea Limitedno ticker on file · SPONSORED ADS | — | 0.00% | $0 | 2.09M | — | 4+ qtrs | ▼ Reduced 4.0% |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 79.9% | $7.2B | 21 |
| No sector on file | 20.1% | $1.8B | 68 |
Questions and answers
What did Baker Brothers own in Q1 2025?
Baker Bros. Advisors's 13F for Q1 2025 lists 89 positions worth $9B. The largest: ONC (26.5%), INCY (20.6%), ACAD (7.9%), MDGL (7.2%), SMMT (5.2%).
What did Baker Brothers buy in Q1 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: IMVT (added, $64.1M), INSM (added, $28.5M), IMCR (added, $24M), PCVX (added, $22.4M), CELC (added, $16M), Verona Pharma Plc (new, $14.2M).
What did Baker Brothers sell in Q1 2025?
The largest sales: ONC (reduced, $199.5M), Ionis Pharmaceuticals Inc (sold out, $29.5M), KRYS (sold out, $26.6M), RYTM (reduced, $25.4M), CRSP (reduced, $22.3M), Akero Therapeutics Inc (reduced, $22.2M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Mar 31, 2025 on May 15, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q1 2025: Baker Bros. Advisors 13F holdings”, data as of 15 May 2025. https://funkfolio.com/gurus/baker-brothers/2025-q1
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Mar 31, 2025.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Mar 31, 2025, filed May 15, 2025. Changes compare share counts with the filing for Dec 31, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 4 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.